Abstract
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
Keywords:
Antibody-drug conjugate; B cell maturation antigen; BCMA; Belantamab mafodotin; Bispecific T cell engager; CAR-T.
MeSH terms
-
Antibodies, Bispecific / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
B-Cell Maturation Antigen / antagonists & inhibitors*
-
B-Cell Maturation Antigen / genetics
-
B-Cell Maturation Antigen / immunology
-
B-Cell Maturation Antigen / physiology
-
B-Lymphocytes / immunology
-
B-Lymphocytes / metabolism
-
B-Lymphocytes / pathology
-
Clinical Trials as Topic
-
Humans
-
Immunoconjugates / therapeutic use
-
Immunotherapy*
-
Immunotherapy, Adoptive
-
Molecular Targeted Therapy*
-
Multicenter Studies as Topic
-
Multiple Myeloma / immunology
-
Multiple Myeloma / therapy*
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / immunology
-
Neoplasm Proteins / physiology
-
Plasma Cells / drug effects
-
Plasma Cells / metabolism
-
Protein Isoforms / antagonists & inhibitors
-
Protein Isoforms / immunology
-
Randomized Controlled Trials as Topic
Substances
-
Antibodies, Bispecific
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
B-Cell Maturation Antigen
-
Immunoconjugates
-
Neoplasm Proteins
-
Protein Isoforms
-
TNFRSF17 protein, human
-
belantamab mafodotin